Johnson & Johnson (JNJ): FY24 Q4 earnings call, Jan 22, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jan 22, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
4 matches for “Tecvayli”; 4 quoted, at least 25 words apart.
…solutions. Just think about multiple myeloma and the impact of DARZALEX, CARVYKTI, TECVAYLI and TALVEY. Think about heart recovery and the impact of Abiomed's Impella…
…our expectations of accelerating growth in the back half of the year. TECVAYLI sales were $146 million in the quarter with growth of 18%, reflecting…
…assets such as DARZALEX, ERLEADA and SPRAVATO. Our recently launched products, CARVYKTI, TECVAYLI and TALVEY and our new launches of TREMFYA in IBD and RYBREVANT…
…come back to that. That includes brands like DARZALEX, CARVYKTI, TALVEY and TECVAYLI as well as ones such as ERLEADA, SPRAVATO and UPTRAVI. We're making…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-01-22:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-01-22:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP